International Biotechnology Trust’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

International Biotechnology Trust’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,800	Closed	-$1.17M	–	68
2022 Q4	$1.17M	Hold	200,800	–	–	0.36%	48
2022 Q3	$1.34M	Buy	200,800 +198,190	+7,593%	+$1.2M	0.43%	47
2022 Q2	$620K	Buy	+2,610	New	+$10.3K	6.47%	1
2019 Q3	–	Sell	-70,000	Closed	-$839K	–	64
2019 Q2	$839K	Buy	+70,000	New	+$753K	0.31%	54

International Biotechnology Trust's CNCE Position: Q1 2023 in Review

International Biotechnology Trust sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 200,800 shares — an estimated $1.17M sold.

International Biotechnology Trust first reported a position in CNCE in Q2 2019 and held it in 4 quarters. The position peaked at $1.34M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

International Biotechnology Trust reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
International Biotechnology Trust sold 200,800 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.17M.
International Biotechnology Trust first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 4 quarters.
International Biotechnology Trust's Concert Pharmaceuticals, Inc. position peaked at $1.34M in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.